Increased Abundances of CD16
HPV
PD-L1
T cells
head and neck cancer
monocyte subsets
oropharyngeal cancer
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
09 Jun 2022
09 Jun 2022
Historique:
received:
09
05
2022
revised:
07
06
2022
accepted:
08
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Patients with human papilloma virus (HPV)-related oropharyngeal cancer have a better prognosis than nonvirally associated patients, most likely because of better immune responses. Increased infiltration of T lymphocytes into the oropharyngeal tumor tissue has been observed, but the dynamics of circulating lymphocytes and monocytes are not fully understood. The aim of this study was to understand the population dynamics of circulating monocyte subsets in oropharyngeal cancer (OPC) patients with regard to the clinicopathological parameters and accompanying immunological consequences in view of the CD4/CD8 T cell subset composition, and the expression of checkpoint pathway proteins programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1). The abundance of circulating monocyte subsets and peripheral blood CD4/CD8 T cells of oropharyngeal cancer patients and their PD-L1 and PD-1 expression levels were analyzed by flow cytometry. The studied oropharyngeal cancer patients revealed heterogeneous individual redistributions of CD14 We conclude that oropharyngeal cancer, as a malignancy from a lymphoid-tissue-rich anatomical region, has a strong systemic impact on the differentiation and regulation of circulating innate and adaptive immune cells. Further comprehensive investigations are required for the possible future usability of the described immunological alterations as bioliquid parameters for prognosis or therapy response prediction.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with human papilloma virus (HPV)-related oropharyngeal cancer have a better prognosis than nonvirally associated patients, most likely because of better immune responses. Increased infiltration of T lymphocytes into the oropharyngeal tumor tissue has been observed, but the dynamics of circulating lymphocytes and monocytes are not fully understood. The aim of this study was to understand the population dynamics of circulating monocyte subsets in oropharyngeal cancer (OPC) patients with regard to the clinicopathological parameters and accompanying immunological consequences in view of the CD4/CD8 T cell subset composition, and the expression of checkpoint pathway proteins programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1).
MATERIALS AND METHODS
METHODS
The abundance of circulating monocyte subsets and peripheral blood CD4/CD8 T cells of oropharyngeal cancer patients and their PD-L1 and PD-1 expression levels were analyzed by flow cytometry.
RESULTS
RESULTS
The studied oropharyngeal cancer patients revealed heterogeneous individual redistributions of CD14
CONCLUSION
CONCLUSIONS
We conclude that oropharyngeal cancer, as a malignancy from a lymphoid-tissue-rich anatomical region, has a strong systemic impact on the differentiation and regulation of circulating innate and adaptive immune cells. Further comprehensive investigations are required for the possible future usability of the described immunological alterations as bioliquid parameters for prognosis or therapy response prediction.
Identifiants
pubmed: 35740384
pii: biomedicines10061363
doi: 10.3390/biomedicines10061363
pmc: PMC9219638
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
APMIS. 2015 Apr;123(4):305-14
pubmed: 25801083
Front Immunol. 2015 Aug 17;6:423
pubmed: 26347746
Head Neck. 2019 Jun;41(6):1880-1888
pubmed: 30636187
Front Oncol. 2021 Sep 24;11:688615
pubmed: 34631523
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Clin Immunol. 2009 Mar;130(3):338-46
pubmed: 18952503
Laryngoscope. 2012 Jan;122(1):121-7
pubmed: 22183632
Clin Immunol. 2021 Apr;225:108677
pubmed: 33476742
PLoS One. 2017 Apr 26;12(4):e0176460
pubmed: 28445506
Lancet. 2004 May 8;363(9420):1488-9
pubmed: 15135592
Front Immunol. 2019 Aug 13;10:1907
pubmed: 31456804
JCO Precis Oncol. 2021 Oct 27;5:
pubmed: 34738049
Ann Oncol. 2010 May;21 Suppl 5:v184-6
pubmed: 20555077
Cell Death Dis. 2019 Jul 15;10(8):540
pubmed: 31308358
Cancer Res. 2014 Dec 1;74(23):6833-44
pubmed: 25273091
Ann Oncol. 2010 Oct;21 Suppl 7:vii243-5
pubmed: 20943622
Front Immunol. 2019 Aug 30;10:2035
pubmed: 31543877
Arthritis Rheum. 2012 Mar;64(3):671-7
pubmed: 22006178
Semin Oncol. 2004 Dec;31(6):744-54
pubmed: 15599852
Sci Rep. 2016 Nov 14;6:36956
pubmed: 27841362
Proc Natl Acad Sci U S A. 1983 Jan;80(2):560-3
pubmed: 6300854
J Immunol. 2021 Jan 1;206(1):51-58
pubmed: 33268482
Front Cell Dev Biol. 2021 Sep 14;9:711348
pubmed: 34595167
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Front Immunol. 2020 Mar 10;11:336
pubmed: 32210959
Cancer. 2001 Dec 1;92(11):2875-84
pubmed: 11753961
Clin Cosmet Investig Dermatol. 2021 Nov 09;14:1629-1636
pubmed: 34803388
Front Cell Dev Biol. 2019 Apr 09;7:52
pubmed: 31024913
Int J Cancer. 2013 Jan 15;132(2):E26-36
pubmed: 22890882
Immunity. 2010 Sep 24;33(3):375-86
pubmed: 20832340
FASEB J. 2003 Feb;17(2):286-8
pubmed: 12490541
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
J Immunol. 2021 Nov 15;207(10):2423-2432
pubmed: 34654687
Immunol Res. 2012 Sep;53(1-3):41-57
pubmed: 22430559
BMC Genomics. 2009 Aug 27;10:403
pubmed: 19712453
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Oral Oncol. 2021 Dec;123:105620
pubmed: 34798575
J Exp Med. 2017 Jul 3;214(7):1913-1923
pubmed: 28606987
Nat Rev Immunol. 2017 Jun;17(6):349-362
pubmed: 28436425
Mod Pathol. 2016 Jul;29(7):753-63
pubmed: 27056074
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Oral Dis. 2013 Sep;19(6):577-84
pubmed: 23176702
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373
Hepatology. 2010 Jan;51(1):154-64
pubmed: 19902483
Front Immunol. 2019 Apr 02;10:653
pubmed: 31001266